Cargando…

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addit...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Marco, Luis, Morillo, Valery, Gorriz, José Luis, Suarez, María K., Nava, Manuel, Ortega, Ángel, Parra, Heliana, Villasmil, Nelson, Rojas-Quintero, Joselyn, Bermúdez, Valmore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592766/ https://www.ncbi.nlm.nih.gov/pubmed/34790827 http://dx.doi.org/10.1155/2021/9032378

Ejemplares similares

Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?
por: Morillas, Carlos, et al.
Publicado: (2021)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

Epicardial Adipose Tissue, Adiponectin and Leptin: A Potential Source of Cardiovascular Risk in Chronic Kidney Disease
por: D’Marco, Luis, et al.
Publicado: (2020)

Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth
por: Rojas, Joselyn, et al.
Publicado: (2014)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
por: Chávez-Castillo, Mervin, et al.
Publicado: (2019)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Advanced Glycation End Products: New Clinical and Molecular Perspectives
por: Salazar, Juan, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

Physiologic Course of Female Reproductive Function: A Molecular Look into the Prologue of Life
por: Rojas, Joselyn, et al.
Publicado: (2015)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies
por: Ludwig, Lisa, et al.
Publicado: (2020)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
por: Trombara, Filippo, et al.
Publicado: (2023)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Diabetic Kidney Disease and COVID-19: The Crash of Two Pandemics
por: D'Marco, Luis, et al.
Publicado: (2020)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Depression as an Immunometabolic Disorder: Exploring Shared Pharmacotherapeutics with Cardiovascular Disease
por: Chávez-Castillo, Mervin, et al.
Publicado: (2020)

Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis
por: Salazar, Juan, et al.
Publicado: (2022)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Koike, Masao, et al.
Publicado: (2021)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis
por: Torres, Wheeler, et al.
Publicado: (2023)

Glucosamine for Osteoarthritis: Biological Effects, Clinical Efficacy, and Safety on Glucose Metabolism
por: Salazar, Juan, et al.
Publicado: (2014)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn L, et al.
Publicado: (2019)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus
por: Rojas, Joselyn, et al.
Publicado: (2014)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review
por: Cano, Raquel, et al.
Publicado: (2021)

Alzheimer’s disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links
por: Rojas, Milagros, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics
por: Salazar, Juan, et al.
Publicado: (2015)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

MON-130 Optimal Glycemic Control in a Patient with HNF1A MODY with GLP1-RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn, et al.
Publicado: (2019)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Low Doses of Melatonin to Improve Sleep in Children with ADHD: An Open-Label Trial
por: Checa-Ros, Ana, et al.
Publicado: (2023)

Relationship between Alcohol Consumption and Components of the Metabolic Syndrome in Adult Population from Maracaibo City, Venezuela
por: Bermúdez, Valmore, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vg1gni7svuebskhcc772tphgi2